科济药业-B(02171)今日盘中股价飙升13.1%,最高升至8.4港元,引发市场高度关注。此前科济药业宣布,其通用型CAR-T细胞疗法CT0590的数据将在美国血液学会年会上公布。
据透露,CT0590研究的初步结果表明该通用型CAR-T细胞疗法的安全性可控,同时实现了深度和持久的临床缓解效果。这一疗法与传统自体CAR-T相比,可大幅降低成本且患者等待时间缩短,被认为具有突破性的可及性改进潜力。
业内分析指出,传统CAR-T疗法面临成本高昂、生产周期长等瓶颈,而通用型CAR-T有望极大提高该疗法的可及性,因此科济药业的CT0590如能持续显示令人信服的数据,未来市场前景广阔。市场对此给予高度认可,推动科济药业股价短暂内飙升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.